Abstract
The two major steps of iodine metabolism—uptake and organification—are altered in thyroid cancer tissues. Organification defects result in a rapid discharge of radioiodine from thyroid cells, a short effective half-life of iodine, and a low rate of thyroid hormone synthesis. These defects are mainly due to decreased expression of functional genes encoding the sodium-iodide symporter and thyroid peroxidase and could result in a low radiation dose to thyroid cancer cells. TSH stimulation that is achieved with injections of recombinant human TSH, or long-term withdrawal of thyroid hormone treatment increases iodine-131 uptake in two-thirds of patients with metastatic disease and increases thyroglobulin production in all patients with metastases, even in the absence of detectable uptake. Serum thyroglobulin determination obtained following TSH stimulation and neck ultrasonography is the most sensitive combination for the detection of small tumor foci. Radioiodine treatment is effective when a high radiation dose can be delivered (in patients with high uptake and retention of radioiodine) and when tumor foci are sensitive to the effects of radiation therapy (younger patients, with a well-differentiated tumor and/or with small metastases). The other patients rarely respond to radioiodine treatment, and when progression occurs, other treatment modalities should be considered. Novel strategies are currently being explored to restore iodine uptake in cancer cells that are unable to concentrate radioiodine.
Key Points
-
The two main biological defects in thyroid cancer tissue are a decreased uptake and a decreased organification of radioiodine
-
These defects are mainly related to decreased gene expression, but post-transcriptional mechanisms may also occur
-
TSH increases expression of thyroid-gland-specific genes, including those encoding the sodium-iodide symporter and thyroglobulin
-
Total-body scanning with radioiodine is less sensitive than the combination of serum thyroglobulin determination following TSH stimulation and neck ultrasonography for the detection of small tumor foci
-
Radioiodine treatment is effective in patients with high uptake of radioiodine who are sensitive to radiation (those who are young, those with a well-differentiated tumor, and those with small metastases)
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schlumberger M (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338: 297–30656
Larsen PR et al. (2003) Thyroid physiology and diagnostic evaluation of patients with thyroid disorders. In Williams' Textbook of Endocrinology, edn 10, 331–373 (Eds Larsen PR et al.) Philadelphia: WB Saunders
Dohan O et al. (2003) The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24: 48–77
Everett LA et al. (1997) Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet 17: 411–422
Rodriguez AM et al. (2002) Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab 87: 3500–3503
Dupuy C et al. (1999) Purification of a novel flavoprotein involved in the thyroid NADPH oxidase. Cloning of the porcine and human cDNAs. J Biol Chem 274: 37625–37629
De Deken X et al. (2000) Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J Biol Chem 275: 23227–23233
Bernier-Valentin F et al. (2006) Three-dimensional organization of thyroid cells into follicle structures is a pivotal factor in the control of sodium/iodide symporter expression. Endocrinology 147: 2035–2042
Bruno R et al. (2005) Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. J Clin Endocrinol Metab 90: 5692–5697
Lazar V et al. (1999) Expression of the Na+/I− symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84: 3228–3234
Lacroix L et al. (2004) Expression of the apical iodide transporter in human thyroid tissues: a comparison study with other iodide transporters. J Clin Endocrinol Metab 89: 1423–1428
Uyttersprot N et al. (1997) Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroid peroxidase and Na+/I− symporter mRNA in dog thyroid. Mol Cell Endocrinol 131: 195–203
Thomas-Morvan C et al. (1974) Thyroid proteins and hormones synthesis in human thyroid cancer. Acta Endocrinol 76: 651–669
Valenta LJ (1976) Thyroid peroxidase, thyroglobulin, cAMP and DNA in human thyroid. J Clin Endocrinol Metab 43: 466–469
Fragu P and Nataf BM (1977) Thyroid peroxidase activity in benign and malignant thyroid disorders. J Clin Endocrinol Metab 45: 1089–1109
Thomas-Morvan C et al. (1982) Thyrotrophin stimulation of adenylate cyclase and iodine uptake in human differentiated thyroid cancer. Acta Endocrinol (Copenh) 101: 25–31
Schurch M et al. (1990) Cold follicles in a multinodular goiter arise partly from a failing iodide pump and partly from deficient iodine organification. J Clin Endocrinol Metab 71: 1224–1229
Boland A et al. (2000) Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 60: 3484–3492
Boland A et al. (2002) Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid 12: 19–26
Lacroix L et al. (2006) HEX, PAX-8, and TTF-1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodine metabolism. Clin Endocrinol 64: 398–404
Lacroix L et al. (2001) Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas. Thyroid 11: 1017–1023
Hooft L et al. (2005) [18F]Fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase expression in the primary tumor. J Clin Endocrinol Metab 90: 328–334
Caillou B et al. (1998) Immunohistochemical detection of the Na+/I− symporter in human thyroid tissues. J Clin Endocrinol Metab 83: 4102–4106
Jhiang SM et al. (1998) An immunohistochemical study of Na+/I− symporter in human thyroid tissues and salivary gland tissues. Endocrinology 139: 4416–4419
Saito T et al. (1998) Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 101: 1296–1300
Trouttet-Masson S et al. (2004) Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. Am J Pathol 165: 25–34
Russo D et al. (2001) Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas. Thyroid 11: 37–39
Di Cristofaro J et al. (2006) Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes. Endocr Relat Cancer 13: 485–495
Missero C et al. (1998) Molecular events involved in differentiation of thyroid follicular cells. Mol Cell Endocrinol 140: 37–43
Knauf JA et al. (2005) Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary cancers that undergo dedifferentiation. Cancer Res 65: 4238–4245
Porra V et al. (2005) Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinoma. J Clin Endocrinol Metab 90: 3028–3035
Fagin JA (2004) Challenging dogma in thyroid cancer molecular genetics. Role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab 89: 4264–4266
Arturi F et al. (1997) Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab 82: 1638–1641
Park HJ et al. (2000) Expression of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinoma. Thyroid 10: 211–217
Arturi F et al. (2000) Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol 143: 623–627
Castro MR et al. (2001) Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 86: 5627–5632
Min JJ et al. (2001) Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 28: 639–645
Schmitz G et al. (2005) Expression of the sodium iodide symporter in differentiated thyroid cancer: clinical evidence. Nuklearmedizin 44: 86–93
Schlumberger M et al. (1983) Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma. J Clin Endocrinol Metab 57: 148–151
Durante C et al. (2006) Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892–289956
Maxon HR and Smith HS (1990) Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin N Am 19: 685–718
Schlumberger M et al. (1980) Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels. J Clin Endocrinol Metab 51: 513–519
Russo D et al. (1997) Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. J Clin Endocrinol Metab 82: 735–738
Meier CA et al. (1994) Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 78: 188–196
Cooper D et al. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 1–33
Pacini F et al. (2006) European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur J Endocrinol 154: 787–803
Pena S et al. (2006) 123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers. J Clin Endocrinol Metab 91: 506–510
Haugen BR et al. (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84: 3877–3885
Schlumberger M et al. (1997) 131I therapy for elevated thyroglobulin levels. Thyroid 7: 273–276
Van Herle AJ et al. (1973) Radioimmunoassay for measurement of thyroglobulin in human serum. J Clin Invest 52: 1320–1327
Preissner CM et al. (2003) Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 88: 3069–3074
Spencer CA et al. (2005) Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 90: 5566–5575
Westbury C et al. (2000) Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid 10: 171–176
Eustatia-Rutten CFA et al. (2004) Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 61: 61–74
Bachelot A et al. (2005) Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf) 62: 376–379
Spitzweg C et al. (1998) Analysis of human iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 83: 1746–1751
Lacroix L et al. (2001) Na(+)/I(−) symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. Eur J Endocrinol 144: 297–302
Tazebay UH et al. (2000) The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 6: 871–878
Bruno R et al. (2004) Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest 27: 1010–1014
Chin BB et al. (2004) Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89: 91–95
Loevinger R et al. (1988) MIRD Primer for Absorbed Dose Calculations. New York: The Society of Nuclear Medicine
Pacini F et al. (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91: 926–932
Hänscheid H et al. (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47: 648–654
Potzi C et al. (2006) Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf) 65: 519–523
Goldman JM et al. (1980) Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 50: 734–739
Robbins RJ et al. (2006) Real-time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning. J Clin Endocrinol Metab 91: 498–505
Sgouros G et al. (2004) Patient specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45: 1366–1372
Lassman M et al. (2004) The impact of I-131 diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 45: 619–625
Postgard P et al. (2002) Stunning of iodine transport by (131)I irradiation in cultured thyroid epithelial cells. J Nucl Med 43: 828–834
Woolfenden JM (2006) Thyroid stunning revisited. J Nucl Med 47: 1403–1405
Mandel SJ and Mandel L (2003) Radioactive iodine and the salivary glands. Thyroid 13: 265–271
Kloos RT et al. (2002) Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 87: 5817–5820
Rubino C et al. (2003) Second primary malignancies in thyroid cancer patients. Br J Cancer 89: 1638–1644
Gruning T et al. (2003) Retinoic acid for redifferentiation of thyroid cancer—does it hold its promise? Eur J Endocrinol 148: 395–402
Haugen BR et al. (2004) Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89: 272–280
Kitazono M et al. (2001) Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of Na+/I− symporter and iodide accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86: 3430–3435
Puppin C et al. (2005) Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 146: 3967–3974
Venkataraman GM et al. (1999) Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I− symporter gene methylation status. J Clin Endocrinol Metab 84: 2449–2457
Shimura H et al. (1997) Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I− symporter gene. Endocrinology 138: 4493–4496
Mandell RB et al. (1999) Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 59: 661–668
Spitzweg C and Morris JC (2004) Gene therapy for thyroid cancer: current status and future prospects. Thyroid 14: 424–434
Koong SS et al. (1999) Lithium as a potent adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 84: 912–916
Dadachova E and Carrasco N (2004) The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med 34: 23–31
O'Reilly MS (2006) Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 16: 45–5055
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M Schlumberger has received research support from Genzyme. The other authors declared they have no competing interests.
Rights and permissions
About this article
Cite this article
Schlumberger, M., Lacroix, L., Russo, D. et al. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Rev Endocrinol 3, 260–269 (2007). https://doi.org/10.1038/ncpendmet0449
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0449
This article is cited by
-
Current practice in patients with differentiated thyroid cancer
Nature Reviews Endocrinology (2021)
-
Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer
Clinical and Translational Oncology (2021)
-
Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto's thyroiditis
Scientific Reports (2020)
-
A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform
BMC Cancer (2019)
-
HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells
Journal of Experimental & Clinical Cancer Research (2019)